An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer

Trial Profile

An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Coronary artery disease; Embolism and thrombosis; Peripheral arterial disorders
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top